drugset / Trial / NCT00469326

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study

NCT00469326 ↗

Phase 3 Completed 200 enrolled University Hospital, Motol
RandomizedParallel-groupOpen-labelPrevention

Summary

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). Patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two days before PCI) and control group (PCI without atorvastatin pretreatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.

Timeline

Start
2005-04
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 80 mg —